Funding	VBG	_
for	IN	_
phage	NN	_
therapy	NN	_
research	NN	_
and	CC	_
clinical	JJ	_
trials	NNS	_
is	VBZ	_
generally	RB	_
insufficient	JJ	_
and	CC	_
difficult	JJ	_
to	TO	_
obtain	VB	_
,	,	_
since	IN	_
it	PRP	_
is	VBZ	_
a	DT	_
lengthy	JJ	_
and	CC	_
complex	JJ	_
process	NN	_
to	IN	_
patent	NN	_
bacteriophage	NN	_
products	NNS	_
.	.	_

Scientists	NNS	CUE-1
comment	NN	_
that	IN	_
'	``	_
the	DT	_
biggest	JJS	_
hurdle	NN	_
is	VBZ	_
regulatory	JJ	_
'	''	_
,	,	_
whereas	IN	_
an	DT	_
official	JJ	_
view	NN	_
is	VBZ	_
that	IN	_
individual	JJ	_
phages	NNS	_
would	MD	_
need	VB	_
proof	NN	_
individually	RB	_
because	IN	_
it	PRP	_
would	MD	_
be	VB	_
too	RB	_
complicated	JJ	_
to	TO	_
do	VB	_
as	IN	_
a	DT	_
combination	NN	_
,	,	_
with	IN	_
many	JJ	_
variables	NNS	_
.	.	_

Due	IN	_
to	IN	_
the	DT	_
specificity	NN	_
of	IN	_
phages	NNS	_
,	,	_
phage	NN	_
therapy	NN	_
would	MD	_
be	VB	_
most	RBS	_
effective	JJ	_
with	IN	_
a	DT	_
cocktail	NN	_
injection	NN	_
,	,	_
which	WDT	_
are	VBP	_
generally	RB	_
rejected	VBN	_
by	IN	_
the	DT	_
U.S.	NNP	_
Food	NNP	_
and	CC	_
Drug	NNP	_
Administration	NNP	_
(	-LRB-	_
FDA	NNP	_
)	-RRB-	_
.	.	_

Public	JJ	_
awareness	NN	_
and	CC	_
education	NN	_
about	IN	_
phage	NN	_
therapy	NN	_
are	VBP	_
generally	RB	_
limited	VBN	_
to	IN	_
scientific	JJ	_
or	CC	_
independent	JJ	_
research	NN	_
rather	RB	_
than	IN	_
mainstream	JJ	_
media	NNS	_
.	.	_

